Peripheral neuropathy is a serious complication of diabetes which can cause a high risk of pain, trophic changes and autonomic dysfunction. A number of clinical trials have established treatments
Peripheral neuropathy is a serious complication of diabetes which can cause a high risk of pain, trophic changes and autonomic dysfunction. A number of clinical trials have established treatments for the symptoms of diabetic peripheral neuropathy (DPN). The only proven treatment strategy that addresses the pathogenic mechanisms is strict glycemic control. Clearly, it is desirable to prevent, impede, or reverse the disrupting and often life-threatening manifestations of peripheral neuropathy by stimulating the growth or regeneration of peripheral nerve axons.
VM202 is a naked plasmid DNA vector engineered to express two isoforms of human hepatocyte growth factor (HGF). HGF, discovered in the early 1980s as a hepatocyte growth factor also has angiogenic and neurotrophic activities. In animal models, HGF encourages regrowth of microvessels and surrounding peripheral nerves, remyelination of damaged peripheral neurons, and neurite outgrowth to reestablish innervation following peripheral nerve injury. It also normalizes pain-related factors that are expressed locally in the area of damaged peripheral nerves, suggesting that it has an overall regenerative effect.
In phase I and phase II clinical studies, subjects treated with VM202 showed significant robust reductions in foot pain and improved sensory function after initial treatment. VM202 has also successfully completed a phase I/II study for amyotrophic lateral sclerosis, also known as Lou Gehrigís disease, which received orphan drug status and fast track designation from the US FDA. An update from an ongoing phase III study for chronic, non-healing foot ulcer associated with diabetes will also be discussed.
(Wednesday) 6:00 pm - 8:00 pm
The Holiday Inn 275 S Airport Blvd South San Francisco